OS Therapies Incorporated (OSTX) Key Metrics
OSTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $61.8M
- Enterprise value
- $77.7M
- P/E (TTM)
- —
- Forward P/E
- 1.7
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 13.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.64
OSTX key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOSTX valuation Price multiples at each fiscal year-end price.
Free cash flow yield−34,758.9 pts
−34,767.1%
2025 · hover or tap a bar for each year
20202025
OSTX returns How much profit the business earns on the capital it uses.
Return on assets−184.2 pts
−464.6%
2025 · hover or tap a bar for each year
20202025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20202025
OSTX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20202025
Earnings per share
−$0.98
2025 · hover or tap a bar for each year
20202025
Free cash flow per share
−$486.74
2025 · hover or tap a bar for each year
20202025
Book value per share
−$0.21
2025 · hover or tap a bar for each year
20202025
Shares outstanding+40.2%
29.3M
2025 · hover or tap a bar for each year
20202025
OSTX financial health Debt, liquidity and how easily interest is covered.
Net debt−$786,303
−$269,830
2025 · hover or tap a bar for each year
20202025
Current ratio−97.6%
0.03
2025 · hover or tap a bar for each year
20202025
OSTX efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−281,540 days
5,830 days
2025 · hover or tap a bar for each year
20202025
OSTX valuation history
Fiscal year-endToday6-year median
OSTX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OSTX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OSTX cash returned to shareholders
DividendsBuybacksFree cash flow
OSTX price vs earnings per share
Share price at year-endEPS (right axis)
OSTX key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $41.0M | $89.3M | — | — | — | — |
| Enterprise value | $40.7M | $89.8M | — | — | — | — |
| Price / book | — | 110.1 | — | — | — | — |
| Earnings yield | −70.2% | −9.9% | — | — | — | — |
| Free cash flow yield | −34,767.1% | −8.2% | — | — | — | — |
| Dividend yield | — | 35.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 35.0% | — | — | — | — |
| Share price at fiscal year-end | $1.40 | $4.28 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$0.98 | −$0.43 | −$0.39 | −$0.27 | −$0.32 | — |
| Operating cash flow per share | −$486.74 | −$0.35 | −$0.15 | −$0.16 | −$0.19 | — |
| Free cash flow per share | −$486.74 | −$0.35 | −$0.15 | −$0.16 | −$0.19 | — |
| Cash per share | $0.01 | $0.27 | $0.00 | $0.01 | $0.00 | — |
| Book value per share | −$0.21 | $0.04 | −$1.20 | −$0.76 | −$0.50 | — |
| Tangible book value per share | −$0.43 | $0.04 | −$1.20 | −$0.76 | −$0.50 | — |
| Dividends per share | — | $1.50 | — | — | — | — |
| Capex per share | $0.02 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Debt per share | — | $0.29 | $0.73 | $0.45 | $0.31 | — |
| Shares outstanding | 29.3M | 20.9M | 20.0M | 23.1M | 23.1M | — |
| Change in shares outstanding | +40.2% | +4.1% | −13.2% | 0.0% | — | — |
| Returns & profitability | ||||||
| Return on assets (ROA) | −464.6% | −280.4% | — | — | −0.9% | −0.0% |
| Return on tangible assets | — | −160.4% | −976.3% | — | — | −0.0% |
| Financial health | ||||||
| Total debt | — | $6.0M | $14.6M | $10.3M | $7.1M | $6.77B |
| Cash & short-term investments | $269,830 | $5.5M | $38,982 | $171,480 | $80,788 | $1.23B |
| Net debt | −$269,830 | $516,473 | $14.6M | $10.2M | $7.0M | $5.54B |
| Debt / equity | — | 7.46 | — | — | — | — |
| Debt / assets | — | 1.09 | 18.31 | 20.33 | 21.70 | 4.04 |
| Current ratio | 0.03 | 1.20 | 0.03 | 0.08 | 0.09 | 0.80 |
| Quick ratio | 0.03 | 1.20 | 0.03 | 0.08 | 0.09 | 0.80 |
| Interest coverage | — | -3.3 | -1.3 | -2.5 | -1.9 | -0.0 |
| Working capital | −$11.4M | $906,217 | −$23.9M | −$5.7M | −$3.2M | −$427.1M |
| Invested capital | −$6.4M | $1.3M | −$9.4M | −$7.4M | −$4.5M | −$786.6M |
| Tangible asset value | −$12.6M | $811,487 | −$24.0M | −$17.6M | −$11.5M | −$6.33B |
| Net current asset value | −$12.6M | $806,217 | −$24.0M | −$17.6M | −$11.5M | −$6.33B |
| Graham net-net per share | −$0.43 | $0.04 | −$1.24 | −$0.77 | −$0.50 | — |
| Capital allocation | ||||||
| Dividends paid | — | $31.2M | — | — | — | — |
| Share buybacks (net) | $0 | — | — | — | — | — |
| Capex / depreciation | 1.28 | 0.00 | 0.00 | 0.00 | 14.82 | 30.06 |
| Efficiency | ||||||
| Days payables outstanding | 5,829.8 | 287,369.7 | 170,414.0 | 471,928.0 | 141.1 | 3,435.3 |
| Receivables turnover | — | — | — | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.06 | 0.00 | 0.00 | 0.00 | 2.59 | 0.11 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | $116,108 | $215.4M | $430.5M |
| Average payables | $5.8M | $2.2M | $2.0M | $1.0M | $448,260 | $40,000 |
| Intangibles / total assets | 95.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from OSTX's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OSTX valuation and financial ratios
See the OSTX income statement, the OSTX chart for price history, or the OSTX stock overview for the latest quote and news.
OSTX key metrics FAQ
What is OS Therapies's free cash flow yield?
OS Therapies generated -$14.2 billion of free cash flow in fiscal 2025, a free cash flow yield of −34,767.1% on its market value at year-end ($41.0 million).
What is OS Therapies's current ratio?
OS Therapies's current ratio was 0.03 at the end of fiscal 2025: current assets were 0.03 times current liabilities.